glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.25700/NJG.2021.01.07glaucoma-316Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF LITERATUREСовременные представления о возможности применения антиангиогенных препаратов в качестве адъювантной терапии при неоваскулярной глаукомеModern concepts on the use of antiangiogenic drugs as adjuvant therapy in neovascular glaucomaБелоусоваЕ. В.BelousovaE. V.

  Белоусова Елена Владимировна, к.м.н., младший научный сотрудник отдела хирургии глаукомы 

127486, Москва, Бескудниковский бульвар, 59а

 Cand. Sci. (Med.), Junior Researcher of the Glaucoma Surgery Department 

59A Beskudnikovsky Blvd., Moscow, 127486

elena.belousova26.08@mail.ruСоколовскаяТ. В.SokolovskayaT. V.

 к.м.н., ведущий научный сотрудник отдела хирургии глаукомы 

127486, Москва, Бескудниковский бульвар, 59а

 Cand. Sci. (Med.), Leading Researcher of the Glaucoma Surgery Department 

59A Beskudnikovsky Blvd., Moscow, 127486

КислицынаН. М.KislitsynaN. M.

 к.м.н., врач-офтальмолог отдела витреоретинальной хирургии и диабета глаза 

127486, Москва, Бескудниковский бульвар, 59а

 Cand. Sci. (Med.), Ophthalmologist at the Department of Vitreoretinal Surgery and Diabetes of the Eye 

59A Beskudnikovsky Blvd., Moscow, 127486

ФГАУ НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова» Минздрава Российской ФедерацииРоссияS.N. Fedorov National Medical Research Center "MNTK "Eye Microsurgery"Russian Federation2021230320212015564Copyright © Белоусова Е.В., Соколовская Т.В., Кислицына Н.М., 20212021Белоусова Е.В., Соколовская Т.В., Кислицына Н.М.Belousova E.V., Sokolovskaya T.V., Kislitsyna N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/316

Выполнен анализ данных литературы о применении современных антиангиогенных лекарственных средств в лечении неоваскулярной глаукомы (НВГ). Приведены сведения о механизмах действия ингибиторов сосудистого фактора роста эндотелия сосудов (VEGF) в качестве адъювантной терапии при НВГ, а также клинической эффективности этих препаратов в отношении модулирования активности процессов заживления тканей глаза после хирургического лечения глаукомы.Рассмотрены результаты исследований применения ингибиторов VEGF: бевацизумаба, ранибизумаба и афлиберцепта при разных путях введения. Указано, что при использовании этих препаратов следует учитывать противопоказания к их применению, а также возможность возникновения побочных эффектов, связанных с интравитреальным путем введения. Отмечено, что эффекты анти-VEGF препаратов в лечении НВГ носят временный характер и длятся обычно 4–6 недель, в связи с этим предполагается, что более выраженным и длительным может быть результат использования комбинации этих лекарственных средств и стандартных методов лечения заболевания.

The article analyzes literature data on the use of modern antiangiogenic drugs in the treatment of neovascular glaucoma (NVG) presenting information on the mechanisms of action of inhibitors of vascular endothelial growth factor (VEGF) as adjuvant therapy in NVG, as well as the clinical effectiveness of these drugs in modulating the activity of ocular tissue healing processes after surgical treatment of glaucoma.The article also considers the results of studies on the use of VEGF inhibitors bevacizumab, ranibizumab, and aflibercept by different routes of administration. Usage of these drugs is indicated to require taking into account the contraindications, as well as the possibility of side effects associated with the intravitreal route of drug administration. The effects of anti-VEGF drugs in the treatment of NVG have been noted to be temporary and last 4–6 weeks, so the result of using a combination of these drugs and standard methods of treating the disease is assumed to be more pronounced and lasting.

неоваскулярная глаукомафильтрационные хирургические вмешательствавнутриглазное давлениесосудистый фактор роста эндотелия сосудовангиогенезбевацизумабранибизумабафлиберцептneovascular glaucomafiltration surgeryintraocular pressurevascular endothelial growth factorangiogenesisbevacizumabranibizumabafliberceptReferencesРыков С.А., Новак Н.В. Эффективность комбинированного метода хирургического лечения вторичной неоваскулярной глаукомы. Офтальмология. Восточная Европа. 2018; 8(2):206-211.Rykov S.A., Novak N.V. The effectiveness of the combined method of surgical treatment of secondary neovascular glaucoma. Oftal'mologiya. Vostochnaya Evropa. 2018; 8(2):206-211. (In Russ.)Бабушкин А.Э. К вопросу о лечении неоваскулярной глаукомы. Точка зрения. Восток – Запад. 2019; 2:120-123. doi:10.25276/2410-1257-2019-2-120-123Babushkin A.E. On the treatment of neovascular glaucoma. Point of view. Vostok – Zapad. 2019; 2:120-123. (In Russ.) doi:10.25276/2410-1257-2019-2-120-123Зотов А.С., Ефремова Т.Г., Нестерова Е.С., Солодкова Е.Г., Балалин С.В. Применение ингибиторов ангиогенеза в комплексном лечении неоваскулярной глаукомы. Современные технологии в офтальмологии. 2019; 4(29):108-111. doi:10.25276/2312-4911-2019-4-108-111Zotov A.S., Efremova T.G., Nesterova E.S., Solodkova E.G., Balalin S.V. The use of angiogenesis inhibitors in the complex treatment of neovascular glaucoma. Sovremennye tekhnologii v oftal'mologii. 2019; 4(29):108-111. (In Russ.) doi:10.25276/2312-4911-2019-4-108-111Карпилова М.А., Дуржинская М.Х. Анти-VEGF-препараты в лечении неоваскулярной глаукомы. Вестник офтальмологии. 2019; 135(5-2):299-304. doi: 10.17116/oftalma2019135052299Karpilova M.A., Durzhinskaya M.Kh. Anti-VEGF-drugs in the treatment of neovascular glaucoma. Bulletin of Ophthalmology. 2019; 135(5-2):299-304. (In Russ.) doi:10.17116/oftalma2019135052299Sun C., Zhang H., Jiang J., Li Y., Nie C., Gu J., Luo L., Wang Z. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2019 Dec 4. doi:10.1007/s10792-019-01207-4Sun C., Zhang H., Jiang J., Li Y., Nie C., Gu J., Luo L., Wang Z. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2019 Dec 4. doi:10.1007/s10792-019-01207-4Du J., Patrie J.T., Prum B.E., Netland P.A., Shildkrot Y.E. Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019; 28(12):1035-1040. doi:10.1097/IJG.0000000000001382Du J., Patrie J.T., Prum B.E., Netland P.A., Shildkrot Y.E. Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019; 28(12):1035-1040. doi:10.1097/IJG.0000000000001382Chen H.J., Ma Z.Z., Li Y., Wang C.G. Change of Vascular Endothelial Growth Factor levels following vitrectomy in eyes with proliferative diabetic retinopathy. J Ophthalmol. 2019; Oct 23;2019:6764932. doi:10.1155/2019/6764932Chen H.J., Ma Z.Z., Li Y., Wang C.G. Change of Vascular Endothelial Growth Factor levels following vitrectomy in eyes with proliferative diabetic retinopathy. J Ophthalmol. 2019; Oct 23;2019:6764932. doi:10.1155/2019/6764932Sun C., Zhang H.S., Yan Y.J., Zhao T., Li A.H., Tang Y., Wang Z.J. Early vitrectomy combined with pan retinal photocoagulation, antivascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma. Chin Med J (Engl). 2019; 132(20):2518-2520. doi:10.1097/CM9.0000000000000482Sun C., Zhang H.S., Yan Y.J., Zhao T., Li A.H., Tang Y., Wang Z.J. Early vitrectomy combined with pan retinal photocoagulation, antivascular endothelial growth factor, and gradual cyclophotocoagulation for treatment of neovascular glaucoma. Chin Med J (Engl). 2019; 132(20):2518-2520. doi:10.1097/CM9.0000000000000482Rong A.J., Swaminathan S.S., Vanner E.A., Parrish R.K. 2nd. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019; 204:62-69. doi:10.1016/j.ajo.2019.02.038Rong A.J., Swaminathan S.S., Vanner E.A., Parrish R.K. 2nd. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol. 2019; 204:62-69. doi:10.1016/j.ajo.2019.02.038Sakamoto M., Hashimoto R., Yoshida I., Ubuka M., Maeno T. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clin Ophthalmol. 2018; 12:2323-2329. doi:10.2147/OPTH.S184959.Sakamoto M., Hashimoto R., Yoshida I., Ubuka M., Maeno T. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clin Ophthalmol. 2018; 12:2323-2329. doi:10.2147/OPTH.S184959.Seibold L.K., Sherwood M.B., Kahook M.Y. Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530–550. doi:10.1016/j.survophthal.2012.01.008Seibold L.K., Sherwood M.B., Kahook M.Y. Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530–550. doi:10.1016/j.survophthal.2012.01.008Saeedi O.J., Jefferys J.L., Solus J.F., Jampel H.D., Quigley H.A. Risk factors for adverse consequences of low intraocular pressure after trabeculectomy. J Glaucoma. 2014; 23(1):e60–8. doi:10.1097/IJG.0000000000000008Saeedi O.J., Jefferys J.L., Solus J.F., Jampel H.D., Quigley H.A. Risk factors for adverse consequences of low intraocular pressure after trabeculectomy. J Glaucoma. 2014; 23(1):e60–8. doi:10.1097/IJG.0000000000000008Daneshvar R. Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res. 2013; 8(2):182–186. PMID: 23943695Daneshvar R. Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res. 2013; 8(2):182–186. PMID: 23943695Park S.C., Su D., Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012; 12(12):1641–1647. doi:10.1517/14712598.2012.721772Park S.C., Su D., Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012; 12(12):1641–1647. doi:10.1517/14712598.2012.721772SooHoo J.R., Seibold L.K., Kahook M.Y. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28(3):165–172. doi:10.3109/08820538.2012.730103SooHoo J.R., Seibold L.K., Kahook M.Y. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28(3):165–172. doi:10.3109/08820538.2012.730103Kim M., Lee C., Payne R., Yue B.Y., Chang J.H., Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol. 2015; 60(6):524–535. doi:10.1016/j.survophthal.2015.04.003Kim M., Lee C., Payne R., Yue B.Y., Chang J.H., Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol. 2015; 60(6):524–535. doi:10.1016/j.survophthal.2015.04.003Kitnarong N., Sriyakul C., Chinwattanakul S. A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther. 2015; 4(1):33–41. doi:10.1007/s40123-015-0033-3Kitnarong N., Sriyakul C., Chinwattanakul S. A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther. 2015; 4(1):33–41. doi:10.1007/s40123-015-0033-3SooHoo J.R., Seibold L.K., Pantcheva M.B., Kahook M.Y. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015; 43(9):803–807. doi:10.1111/ceo.12559SooHoo J.R., Seibold L.K., Pantcheva M.B., Kahook M.Y. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015; 43(9):803–807. doi:10.1111/ceo.12559Magdelaine-Beuzelin C., Pinault C., Paintaud G., Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2010; 2(2):176–180. doi:10.4161/mabs.2.2.11205Magdelaine-Beuzelin C., Pinault C., Paintaud G., Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2010; 2(2):176–180. doi:10.4161/mabs.2.2.11205Simha A., Braganza A., Abraham L., Samuel P., Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013; 10:CD007920. doi:10.1002/14651858Simha A., Braganza A., Abraham L., Samuel P., Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013; 10:CD007920. doi:10.1002/14651858Waisbourd M., Shemesh G., Kurtz S., Rachmiel R., Moisseiev E., ZayitSoudri S., Loewenstein A., Barequet I. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014; 93(3-4): 108–112. doi:10.1159/000358600Waisbourd M., Shemesh G., Kurtz S., Rachmiel R., Moisseiev E., ZayitSoudri S., Loewenstein A., Barequet I. Topical bevacizumab for neovascular glaucoma: a pilot study. Pharmacology. 2014; 93(3-4): 108–112. doi:10.1159/000358600Duch S., Buchacra O., Milla E., Andreu D., Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009; 18(2):140–143. doi:10.1097/IJG.0b013e318170a747Duch S., Buchacra O., Milla E., Andreu D., Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009; 18(2):140–143. doi:10.1097/IJG.0b013e318170a747Luke J., Nassar K., Luke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10):2403–2413. doi:10.1007/s00417-013-2428-yLuke J., Nassar K., Luke M., Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10):2403–2413. doi:10.1007/s00417-013-2428-yGrover S., Gupta S., Sharma R., Brar V.S., Chalam K.V. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009; 93(2):273–274. doi:10.1136/bjo.2008.145714Grover S., Gupta S., Sharma R., Brar V.S., Chalam K.V. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009; 93(2):273–274. doi:10.1136/bjo.2008.145714Sugimoto Y., Mochizuki H., Okumichi H., Takumida M., Takamatsu M., Kawamata S., Kiuchi Y. et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1601–1609. doi:10.1007/s00417-010-1406-xSugimoto Y., Mochizuki H., Okumichi H., Takumida M., Takamatsu M., Kawamata S., Kiuchi Y. et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1601–1609. doi:10.1007/s00417-010-1406-xMuhsen S., Compan J., Lai T., Kranemann C., Birt C. Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma. Int J Ophthalmol. 2019; 12(10):1567-1574. doi:10.18240/ijo.2019.10.08Muhsen S., Compan J., Lai T., Kranemann C., Birt C. Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma. Int J Ophthalmol. 2019; 12(10):1567-1574. doi:10.18240/ijo.2019.10.08Elwehidy A.S., Bayoumi N.H., Badawi A.E., Hagras S.M., Abdelkader A. Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila). 2019; 8(4):308-313. doi:10.1097/APO.0000000000000248Elwehidy A.S., Bayoumi N.H., Badawi A.E., Hagras S.M., Abdelkader A. Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila). 2019; 8(4):308-313. doi:10.1097/APO.0000000000000248Li Z., Van Bergen T., Van de Veire S., Van de Vel I., Moreau H., Dewerchin M., Maudgal P.C., Zeyen T., Spileers W., Moons L., Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009; 50(11):5217–5225. doi:10.1167/iovs.08-2662Li Z., Van Bergen T., Van de Veire S., Van de Vel I., Moreau H., Dewerchin M., Maudgal P.C., Zeyen T., Spileers W., Moons L., Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009; 50(11):5217–5225. doi:10.1167/iovs.08-2662Memarzadeh F., Varma R., Lin L.T., Parikh J.G., Dustin L., Alcaraz A., Eliott D. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009; 50(7):3233–3237. doi:10.1167/iovs.08-2441Memarzadeh F., Varma R., Lin L.T., Parikh J.G., Dustin L., Alcaraz A., Eliott D. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009; 50(7):3233–3237. doi:10.1167/iovs.08-2441Ozgonul C., Mumcuoglu T., Gunal A. The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res. 2014; 39(5):451–459. doi:10.3109/02713683.2013.851704Ozgonul C., Mumcuoglu T., Gunal A. The effect of bevacizumab on wound healing modulation in an experimental trabeculectomy model. Curr Eye Res. 2014; 39(5):451–459. doi:10.3109/02713683.2013.851704Sengupta S., Venkatesh R., Ravindran R.D. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma. 2012; 21(7):450–459. doi:10.1097/IJG.0b013e31821826b2Sengupta S., Venkatesh R., Ravindran R.D. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma. 2012; 21(7):450–459. doi:10.1097/IJG.0b013e31821826b2Tai T.Y., Moster M.R., Pro M.J., Myers J.S., Katz L.J. Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma. 2015; 24(4):311–315. doi:10.1097/IJG.0b013e31829f9bd3Tai T.Y., Moster M.R., Pro M.J., Myers J.S., Katz L.J. Needle bleb revision with bevacizumab and mitomycin C compared with mitomycin C alone for failing filtration blebs. J Glaucoma. 2015; 24(4):311–315. doi:10.1097/IJG.0b013e31829f9bd3Pro M.J., Freidl K.B., Neylan C.J., Sawchyn A.K., Wizov S.S., Moster M.R. Ranibizumab versus mitomycin C in primary trabeculectomy — a pilot study. Curr Eye Res. 2015; 40(5):510–515. doi:10.3109/02713683.2014.935441Pro M.J., Freidl K.B., Neylan C.J., Sawchyn A.K., Wizov S.S., Moster M.R. Ranibizumab versus mitomycin C in primary trabeculectomy — a pilot study. Curr Eye Res. 2015; 40(5):510–515. doi:10.3109/02713683.2014.935441Nilforushan N., Yadgari M., Kish S.K., Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012; 153(2):352–7.e1. doi:10.1016/j.ajo.2011.08.005Nilforushan N., Yadgari M., Kish S.K., Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012; 153(2):352–7.e1. doi:10.1016/j.ajo.2011.08.005Akkan J.U., Cilsim S. Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma. 2015; 24(1):1–8. doi:10.1097/IJG.0b013e318287abf3Akkan J.U., Cilsim S. Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma. 2015; 24(1):1–8. doi:10.1097/IJG.0b013e318287abf3Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(10):4807–13. doi:10.1167/iovs.08-3148Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(10):4807–13. doi:10.1167/iovs.08-3148Jurkowska-Dudzinґska J., Kosior-Jarecka E., Zarnowski T. Comparison of the use of 5-flfluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Exp Ophthalmol. 2012; 40(4):e135– 42. doi:10.1111/j.1442-9071.2011.02608.xJurkowska-Dudzinґska J., Kosior-Jarecka E., Zarnowski T. Comparison of the use of 5-flfluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Exp Ophthalmol. 2012; 40(4):e135– 42. doi:10.1111/j.1442-9071.2011.02608.xVandewalle E., Abegão Pinto L., Van Bergen T., Spielberg L., Fieuws S., Moons L., Spileers W., Zeyen T., Stalmans I. et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014; 98(1):73–78. doi:10.1136/bjophthalmol-2013-303966Vandewalle E., Abegão Pinto L., Van Bergen T., Spielberg L., Fieuws S., Moons L., Spileers W., Zeyen T., Stalmans I. et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014; 98(1):73–78. doi:10.1136/bjophthalmol-2013-303966Hau S., Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol. 2009; 20(2):131–136. doi:10.1097/ICU.0b013e328325a54bHau S., Barton K. Corneal complications of glaucoma surgery. Curr Opin Ophthalmol. 2009; 20(2):131–136. doi:10.1097/ICU.0b013e328325a54bYoeruek E., Spitzer M.S., Tatar O., Aisenbrey S., Bartz-Schmidt K.U., Szurman P. Safety profifile of bevacizumab on cultured human corneal cells. Cornea. 2007; 26(8):977–982. doi:10.1097/ICO.0b013e3180de1d0aYoeruek E., Spitzer M.S., Tatar O., Aisenbrey S., Bartz-Schmidt K.U., Szurman P. Safety profifile of bevacizumab on cultured human corneal cells. Cornea. 2007; 26(8):977–982. doi:10.1097/ICO.0b013e3180de1d0aBochmann F., Kaufmann C., Becht C.N., Guber I., Kaiser M., Bachmann L.M., Thiel M.A. et al. ISRCTN12125882-inflfluence of topical anti-VEGF Ranibizumab) on the outcome of filtration surgery for glaucoma-study protocol. BMC Ophthalmol. 2011; 11:1. doi:10.1186/1471-2415-11-1Bochmann F., Kaufmann C., Becht C.N., Guber I., Kaiser M., Bachmann L.M., Thiel M.A. et al. ISRCTN12125882-inflfluence of topical anti-VEGF Ranibizumab) on the outcome of filtration surgery for glaucoma-study protocol. BMC Ophthalmol. 2011; 11:1. doi:10.1186/1471-2415-11-1Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005; 118(Pt 16):3759–68. doi:10.1242/jcs.02483Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005; 118(Pt 16):3759–68. doi:10.1242/jcs.02483Liu X., Du L., Li N. The effects of bevacizumab in augmenting trabeculectomy for glaucoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(15):e3223. doi:10.1097/MD.0000000000003223Liu X., Du L., Li N. The effects of bevacizumab in augmenting trabeculectomy for glaucoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(15):e3223. doi:10.1097/MD.0000000000003223

The authors declare that there are no conflicts of interest present.